This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia - Module - 1

New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia - Module - 1

Format

Webcast

Time to Complete

2 hours

Released

May 13, 2019

Expires

May 13, 2020
Add to Queue


Maximum Credits

2.00/ AMA PRA Category 1 Credit(s)TM
2.00 / CE for Nurses
2.00 / CE for Pharmacists

Accredited Provider

Jointly provided by The A. Webb Roberts Center for CME of Baylor Scott & White Health, Amedco and CancerNet, LLC

Commercial Supporter

Supported by Novartis Pharmaceuticals Corporation and Takeda Oncology

Program Description

This webcast is intended to improve care of patients with leukemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Intended Audience

This webcast is designed to meet the educational needs of hematologists/oncologists and other health care professionals who diagnose, treat, and manage patients leukemia. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Educational Objectives

As a result of participating in the activity, learners should be better able to:

  • Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)
  • Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents
  • Describe the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)
  • Identify the novel therapeutic options for adolescents and young adults (AYA) relapsed/ refractory Philadelphia-positive and Philadelphia-negative patients with ALL

Conflict Of Interest Disclosure Policy

It is the policy of the The A. Webb Roberts Center for CME of Baylor Scott & White Health and Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.

Faculty

Courtney DiNardo, MD
Assistant Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. DiNardo discloses the following:
Research support (to institution): Abbvie, Agios, Bayer, Calithera, Celgene, Daiichi-Sankyo, Novartis
Consultant or Member of Advisory Boards: Abbvie, Agios, Bayer, Celgene, Jazz, Karyopharm, MedImmune, Syros

Elias Jabbour, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Jabbour discloses the following:
Research grants: Pfizer, Takeda, Amgen, Abbvie, Novartis
Consultant or Member of Advisory Boards: Pfizer, Takeda, Amgen, Abbvie, BMS

Nitin Jain, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Jain discloses the following:
Research funding: Pharmacyclics, AbbVie, Genentech, BMS, Pfizer, ADC Therapeutics, Seattle Genetics, Incyte, Celgene, AstraZeneca, Servier, Cellectis, Verastem, Adaptive Biotechnologies, Precision Biosciences
Consultant or Member of Advisory Boards: Pharmacyclics, AbbVie, Genentech, AstraZeneca, Verastem, Pfizer, Servier, Adaptive Biotechnologies, Janssen, Precision Biosciences

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE webcast:

Kamatham A. Naidu, PhD (CancerNet, LLC), has no relevant financial relationships to disclose.
Brian Waggoner (CancerNet, LLC), has no relevant financial relationships to disclose.

Credit

2.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement


This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet, LLC. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.00

Type

CE for Nurses

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 2.00 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Credit

2.00

Type

CE for Pharmacists

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Amedco LLC designates this enduring activity for a maximum of 2.00 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. Event UAN: JA4008163-9999-19-015-L04-P

Disclosure of Unlabeled Use

It is the policy of The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.

Disclaimer

The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Non-Endorsement of Products

Amedco does not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.

Instructions

There are no fees for participating and receiving CME credit for this webcast. During the period May 8, 2019 through May 8, 2020, participants must read all the material and study the educational webcast.

This webcast includes text, graphics, and may include multimedia features.

To obtain credit, a score of 80% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and Amedco observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue